A phase III clinical trial of Pepinemab in Huntington's Disease
Latest Information Update: 22 May 2023
Price :
$35 *
At a glance
- Drugs Pepinemab (Primary)
- Indications Huntington's disease
- Focus Therapeutic Use
- 15 May 2023 According to Vaccinex media release, company has submitted briefing documents along with a Type C meeting request to the FDA related to the proposed plan for a this study and FDA has indicated that they expect to provide a written response later this month to the questions posed in the briefing package.
- 08 Nov 2021 According to Vaccinex media release, this trial will be held in collaboration with a biopharmaceutical partner and the discussions are ongoing.
- 24 May 2021 New trial record